Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.
My understanding is weekly review i.e. dose and check etc. 6wks the dose escalation if no mtd found.
So we first dosed on 6th June and by now should have news of move to next cohort by now. Now remember Sareum have no control over the trial it is the safety committee running the show- so with that in mind my only guess as to why there could be a delay is either 1. Mtd found so now designing a trial for ph1b (unlikely)
2. Just waiting for safety committe to give the go ahead for the next cohort or 3. No where near mtd i.e. no adverse effects observed at all in the slightest- so safety committee are now deciding on the next dose escalation amount and could change the trial design for ph1a if the capsule exceeded expectations (again unlikely, but stranger things have happened and we are not allosteric all out Tyk2 as we are Jak1 as well and pre-clinically we aced selectivity and no tox or mtd was found).
Sad, Citizen, RMM care to comment on point 3 being a potential reason for delay.
Those of us who have been here a while know how quickly the price can move up as well as down.
It is important to take stock of where we are in order to decide what is really going on behind the scenes- we are a clinical stage company with a 100% owned molecule which insofar unable to find any tox or mtd we are embarking on a trial with a once daily capsule targeting Psoriasis which effects more than 60 million adults worldwide, with a market size for potential treatments estimated to be worth more than US$30 billion.
We first in-human dosed on 6th June this year and the trial is being controlled by the safety committee who are independent and cannot be influenced by Sareum and have insofar not halted the trial on safety grounds.
6 weeks in and normally unless bad news announced, which would have been by now, the dosage increases to the next cohort which normally had to be RNS'd.
Many happy returns chaps-, Give it a thought and then consider whether this current price is a true reflection of current progress.
Your right because mining for metals and discovering cures and treatments for auto-immune illnesses and cancer have alot in common- so in turn investors and fund raises and placing of such will have a similar amount and takeup too. Complete Ta.tfuddery
No need to call a broker sweetie most here like me have a long term horizon and likely sitting on a free ride (39k encounting holding myself).
Comfortably in profit watching the price ping pong so, having fun c.. womble bashing and waiting for the inevitable green light from the safety committee to increase dosage to the next cohort (1st dosed 6th June and trial not stopped), then again and possibly again until mtd is found.
Then ph1b efficacy described as gamechanging by Dr Reader- we be chilled sweetie pie.
Oh aye, we're all quacking in our little boots. We've seen you type a many a time before.
And even if we raised it would be oversubscribed as all the others were before we were a clinical stage bio. And the BOD have advised they may do so at ph1b but we are only in ph1a so a long way to go. But even then we will have chosen a mtd and know the level of tox and will be going into hospital patients for efficacy so the value of the once daily capsule will have trebled you t.at.
I think if we show any efficacy in ph1b with 1801 (which this point we will have found mtd and know what the tox level is) then a licence will in the offing no doubt as I don't believe Sareum want to go anywhere near ph2 if they can help it due to cost, so would rather take the money to push 1802 (the biggie).
In regards to 1802, Potnak is right we would need some form of ph1 but they have already done acute tox studies and have already advised the trial will be very different to 1801 and going straight into patients not healthy subjects.
https://m.youtube.com/watch?v=KJFhOEmaPFw
26.15- 1802 translation studies are in progress and done some short term acute tox studies already all of which were fine. Manufacture will be in line with 1801 process so no hanging about when they are ready.
27.20- 1802 will begin clinical trials in patients not healthy subjects.
Australia is built on first-in-human on healthy subjects so may not be in Australia.
And will be quiete a different ph1 clinical trial than that envisaged for 1801.
Sad, your on the right path there chap. Dr Reader has already expressed at the AGM that 1801 could be going outside of Psoriasis.
AGM-
https://m.youtube.com/watch?v=1x1_ktQPLik
1:03- Dr Reader very much gunning for partnering early or late clincial and also advising 1801 could be licenced and used in other indications- he has a suspicion that Jak1/Tyk2 pathway could be used in several different therapeutic areas.
As I said earlier to bluenose t.at but my post was removed for obvious reasons. That I don't ramp just try to put out reminders (with maybe a little over enthusiam but rightly so as we have a 100% owned compound in in-human clinical stage trials) that everything in the world of Sareum is not about to collapse as him and band of merry t.ats seem to suggest.
The price is what it is for no news and will ping pong about but we are in ph1a and still going strong no safety issues (Sareum have no control of the trial the safety committee do)- And the exciting thing is 1802 has also been given a patent to branch out into auto-immune as well as cancer.
Many happy returns chaps.
Lesson 1
Bashers never bash bad stocks. You can watch the board for stocks with no potential. You’ll see pretty quickly that those stocks don’t have bashers. Bashers only go after stocks that are going upwards or have excellent potential to go up. Bashers get left behind, so they want to bring the price down.
Lesson 7: Bashers play on your lack of patience. You have held a stock for a while. You knew it will be a big stock someday, but the BASHER CAN GET TO YOU BECAUSE YOU ARE TIRED OF WAITING FOR YOUR GAIN. That's when the Basher is best. You are tired. You have forgotten the goal for the stock was to hold it for one year. The Basher is bothersome, so you dump it on a bad day. Some others also dump. Then you get mad for your loss and return to let everyone know how mad you are. Then you turn into a semi-Basher as well. THE BASHER HAS WON, AND GAINED A NEW ALLY - YOU!
Lesson 8: BRING THE PRICE DOWN. That is the Basher's job. The truth is not important. Lies are the norm. Post continuously on the board every day. They are trying to scare the newbies that are just investigating a stock. They are trying to wear down the faithful longs on the board and gain free reign and control and they will do whatever it takes.
Been posted before a very longtime ago. But a good reminder as to why some sealions turn up when we are on the way down
We should be getting news of a cohort increase shortly as been 6 weeks since first done 6th June. Safety committee must be happy to allow a dosage increase as trial has not been stopped.
So we edge closer to finding mtd then ph1b efficacy by which time the likes of this dirt will be gone but unfortunately replaced with a more researched and obtuse type. Bashers don't bash bad stocks as we know.
To lose credibility when spelling something wrong. don't think so, a person maybe dyslexic have you considered that.
Nonetheless, it is what you post that gains or loses so called credibility it's a public anonymous board no one is going to lose anything you t.at- when you post fud at least back it up with research, facts, rns info and evidence for starters if you're so concerned about so called credibility.
Surfie, I feel God is on our side to br honest you complete utter t.at.
And in regards to what I am taking well this-
June 2023- 1801
The China National Intellectual Property Administration (CNIPA) has officially issued patent number CN113056456B, safeguarding SDC-1801 and medical applications of it in treating inflammatory or immune disorders.
1802-
SDC-1802 is a TYK2/JAK1 inhibitor being developed for cancer immunotherapy. Sareum continues to work on the translational studies needed to support the development of SDC-1802, defining the optimal cancer application prior to completing toxicology and manufacturing studies.
The United States Patent and Trademark Office (USPTO) has formally granted patent number US 11,673,870 B2 specifically covering the treatment of autoimmune disorders with SDC-1802 and several analogues. While Sareum has previously secured international patents providing comprehensive protection for the compound SDC-1802, this patent extends its scope in the US beyond immuno-oncology.
Seen as we are in ph1a safety 1st dosed 6th June, safety committee not halted the trial Australia has a direct route to China and 1802 will 1. Use 1801 learnings for progress and 2. Can be a backup for auto-immune now or Lupus as trialled successfully by the US Army for Lupus- how is that for a double dose.
Warthog, like most long-termers we feel your pain. But we are in a totally different position from the jam tomorrow scenario to be honest.
We are now a clinical stage company and our capsule is being taken by humans not mice, the trial is under the control of the safety committe so Sareum have not control over it.
In regards to how long would a person be willing to hang on- well seen as we are in ph1 safety 1st dosed on 6 June and the trial has not been stopped. And Dr Reader has specified ph1b as gamechanging- I would guess wait until next year to see how efficacy is turning out and then make a decision.
In my opinion if we are still little to no tox and high mtd come ph1b then the price will be above £2 as the safety of the capsule will have been proven taking into hospital patients and this current price malarky will be a blip in the grander scheme of things.
Many happy returns chaps- But as always lets see how things pan out, a long way to go and still risky but we are a totally different animal and clinical stage company with a once daily capsule earmarked to potentially treat Psoriasis and p.ss on Abbvie's Humira parade.
Sfif, your right its going to be 30p placing and we'll get some bangers and mash as recompense. Now the question is what on earth are you doing on this board where have you been all these years- you should be on the non.exec committee.
There 2 ph1b licensing deals no. 7 and 11 here-
https://www.fiercebiotech.com/special-report/top-15-biopharma-licensing-deals-2019
But all depends on how good the data is at the end of the day which determine any deal.
Sure Krone, but it should still see us through ph1a I believe unless someone can state otherwise. Additionally Sareum will no doubt claim that potential 43% of R&D costs as cash so that will also assist the cause.
Nonetheless, a raise eitherway is required for ph1b but would not be a negative thing by any stretch of the imagination as we would be gunning for efficacy which is where the big deals normally happen as Potnak has pointed out.
For those who fear a placing-
We have enough to get us through ph1a do up to next year-
Cash at 31 December 2022 of £2.9m (£5.6m as of 31 December 2021 and £4.3m as of 30 June 2022).
Additionally-
Australia offers state-of-the-art research facilities and an efficient approval process, making it an attractive location for research and development. Moreover, the country provides significant tax incentives for companies that conduct their research there, allowing them to claim up to 43.5% of their eligible R&D expenditure as a cash payment. As such, Sareum has established the required local presence by setting up a legal entity in Australia.
Furthermore-
The Phase 1a part of the trial is expected to provide safety and dosing information applicable for any future trials in patients with other autoimmune diseases, and potentially in patients with the acute respiratory symptoms of viral infections should the Company decide to progress such trials.
Provided satisfactory safety data is obtained from this initial safety and dosing study, and subject to additional funding, a Phase 1b clinical study will commence in psoriasis patients.
So they mention needing funding in ph1b but only if they go down the respiratory and viral infections. So relax and lets see how things pan out.
And as mentioned early if we do raise it will likely be oversubscribed like all the previous one when we not in clinic. So at ph1b that means we have found mtd and are going for efficacy in patients at hospital for which Dr Reader described as gamechanging.
Those of us who have been here a while know how quickly the price can move up as well as down.
It is important to take stock of where we are in order to decide what is really going on behind the scenes- we are a clinical stage company with a 100% owned molecule which insofar unable to find any tox or mtd we are embarking on a trial with a once daily capsule targeting Psoriasis which effects more than 60 million adults worldwide, with a market size for potential treatments estimated to be worth more than US$30 billion.
We first in-human dosed on 6th June this year and the trial is being controlled by the safety committee who are independent and cannot be influenced by Sareum and have insofar not halted the trial on safety grounds.
6 weeks in and normally unless bad news announced, which would have been by now, the dosage increases to the next cohort which normally had to be RNS'd.
Many happy returns chaps-, Give it a thought and then consider whether this current price is a true reflection of current progress.